Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics (DE:6A3A)
:6A3A
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.2Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 16.50%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a strong start for AUCATZYL with significant interest and revenue generation. Geographic expansion and promising data in autoimmune diseases further bolstered positive outlooks. However, high costs and increased net loss present financial challenges that need addressing.Company Guidance
During the Autolus First Quarter 2025 Financial Results Conference Call, guidance was provided on several key metrics. The company reported $9 million in recognized revenue for Q1 2025, marking a strong start for AUCATZYL's U.S. launch. Additionally, they have authorized 39 clinical centers to deliver AUCATZYL, covering about 90% of total U.S. medical lives. The Centers for Medicare & Medicaid Services (CMS) published reimbursement codes for AUCATZYL on April 1, facilitating its eligibility for reimbursement under government programs. Looking ahead, Autolus plans to increase the number of centers to approximately 60 by year-end, aiming for broad patient access. They also highlighted the potential geographic expansion into the UK, having received conditional marketing authorization from the MHRA, and are engaging with relevant bodies for reimbursement processes. Autolus' cash position at the end of Q1 2025 was $516.6 million, down from $588 million at the end of December 2024, primarily due to operating and investing activities. The company maintains confidence in its financial foundation to support ongoing commercialization efforts and clinical trials.Strong Launch of AUCATZYL
Autolus reported $9 million in recognized revenue in the first quarter from the launch of AUCATZYL. The product has been well-received, with 39 centers authorized to deliver it and approximately 90% of total U.S. medical lives covered.
Geographic Expansion
Autolus received conditional marketing authorization from the MHRA in the UK and is engaging with NICE for reimbursement. Progression in Europe is ongoing, with an expected decision from the European agency in the second half of the year.
Positive Developments in Autoimmune Disease
Phase 1 CARLYSLE study in Systemic Lupus Erythematosus showed promising results, with patients achieving renal complete remissions and no neurological toxicities observed.
Financial Stability
Autolus ended Q1 2025 with $516.6 million in cash, cash equivalents, and marketable securities, providing a strong foundation for ongoing and future projects.
---
DE:6A3A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:6A3A Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | €1.03 | €1.08 | +4.85% |
Mar 20, 2025 | €1.62 | €1.63 | +0.62% |
Nov 12, 2024 | €3.56 | €3.34 | -6.18% |
Aug 08, 2024 | €3.66 | €3.62 | -1.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Autolus Therapeutics (DE:6A3A) report earnings?
Autolus Therapeutics (DE:6A3A) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Autolus Therapeutics (DE:6A3A) earnings time?
Autolus Therapeutics (DE:6A3A) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Autolus Therapeutics stock?
The P/E ratio of Autolus Therapeutics is N/A.
What is DE:6A3A EPS forecast?
DE:6A3A EPS forecast for the fiscal quarter 2025 (Q2) is -0.21.
---